EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial.

Tore Wergeland iD, Melanie Simpson iD, Irina Aschehoug, Lise Øie, Sozaburo Hara, Einar Tobias Vassbø Skalstad iD, Øyvind Salvesen, Erling Tronvik, Daniel Bratbak

F1000Research · 2026

DOI: 10.12688/f1000research.164241.2 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift F1000Research, 2026. Verfasst von Tore Wergeland und 8 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Headache Research (NorHEAD), Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders, Sphenopalatine Ganglion Block. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Norwegian National Program for Clinical Therapy Research, KLINBEFORSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment-resistant chronic migraine patients constitute a heavily burdened patient population with need for novel treatment options. The sphenopalatine ganglion (SPG), located deep within the facial structures, is a synaptic junction in the trigemino-autonomic reflex that is hypothesised to play a part in migraine pathophysiology. A 2017 open-label pilot study explored the SPG as a target for onabotulinumtoxinA injections in chronic migraine using a navigation-guided injection device, demonstrating a favourable safety profile and promising response on migraine related efficacy outcomes.

Methods

MiBlock is a multi-centre, investigator-initiated, publicly funded, randomised, quadruple-blinded and placebo-controlled trial. Participation is voluntary and all participants must sign a written consent prior to inclusion. The study is approved by the Norwegian ethics committee and the Norwegian Medical Product Agency. Patients with treatment-resistant chronic migraine will be recruited from four Norwegian university hospitals until 170 have received study treatment. The study will investigate the efficacy of a single-session, bilateral, navigation-guided, percutaneous injection of either onabotulinumtoxinA (verum) or 0.9% NaCl (placebo) towards the SPG under local anaesthesia. The primary efficacy endpoint is the change from baseline in the frequency of moderate and severe headache days at weeks 5-8 post-injection. The primary efficacy outcome variable is collected prospectively through daily headache eDiary entries during the entire study participation. The treatment effect will be assessed by comparing the placebo and the treatment arm according to a prespecified statistical analysis plan.

Discussion

This trial addresses a novel treatment strategy in headache prevention. The study is designed to evaluate the efficacy and safety of onabotulinumtoxinA injection towards the SPG in chronic migraine, but results may shed light on the feasibility of navigation-guided SPG injections in several headache disorders. Results will be published in international open-access peer-reviewed journals. Trial registration number EudraCT number: 2018-004053-24. ClinicalTrial ref: NCT04069897. Protocol version 4.2, Date 21.11.2019

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersSphenopalatine Ganglion BlockHumansRandomized Controlled Trials as TopicChronic DiseaseMulticenter Studies as TopicFemaleAdultMiddle AgedMalePilot ProjectsTreatment Outcome

Stichwörter der Autor:innen

Sphenopalatine ganglionchronic migrainemigraine prevention

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin A

Autor:innen und Institutionen

  • Norwegian Centre for Headache Research (NorHEAD), Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of neurology and neurophysiology, St Olav's University Hospital, Trondheim, Norway.
  • Department of Neuromedicine and Movement Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neurosurgery, St Olav's University Hospital, Trondheim, Norway.
  • Faculty of medicine and health sciences, Norwegian University of Science and Technology, Trondheim, Norway.

ORCID-Profile: Tore Wergeland, Melanie Simpson, Einar Tobias Vassbø Skalstad

Förderung

  • the Norwegian National Program for Clinical Therapy Research, KLINBEFORSK

Zitieren

APA

Wergeland, T., Simpson, M., Aschehoug, I., Øie, L., Hara, S., Skalstad, E. T. V., Salvesen, Ø., Tronvik, E., & Bratbak, D. (2026). OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial. F1000Research. https://doi.org/10.12688/f1000research.164241.2

Vancouver

Wergeland T, Simpson M, Aschehoug I, Øie L, Hara S, Skalstad ETV, et al. OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial. F1000Research. 2026. doi:10.12688/f1000research.164241.2

BibTeX
@article{Wergeland2026,
  author = {Wergeland, Tore and Simpson, Melanie and Aschehoug, Irina and Øie, Lise and Hara, Sozaburo and Skalstad, Einar Tobias Vassbø and Salvesen, Øyvind and Tronvik, Erling and Bratbak, Daniel},
  title = {OnabotulinumtoxinA blockade of the sphenopalatine ganglion in treatment-resistant chronic migraine (MiBlock): rationale, design and study protocol for a multi-centre, investigator initiated, randomised, quadruple-blinded placebo-controlled trial},
  journal = {F1000Research},
  year = {2026},
  doi = {10.12688/f1000research.164241.2}
}
Kostenlos starten →